A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia

Kathryn M. Connor, Erin Mahoney, Saheeda Jackson, Jill Hutzelmann, Xin Zhao, Nan Jia, Ellen Snyder, Duane Snavely, David Michelson, Thomas Roth, W. Joseph Herring

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia'. Together they form a unique fingerprint.

Medicine & Life Sciences